cis-1-trifluoromethyl-4-methylcyclohexane | 13127-02-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: cis-1-trifluoromethyl-4-methylcyclohexane
• 英文别名: cis-4-Methyl-trifluormethyl-cyclohexan；cis-1-Methyl-4-trifluormethyl-cyclohexan
• CAS: 13127-02-1
• 化学式: C₈H₁₃F₃
• 分子量: 166.186
• InChiKey: YZKFCSOACWTUBF-KNVOCYPGSA-N

物化性质

• 沸点：
  122.7±35.0 °C(Predicted)
• 密度：
  1.041±0.06 g/cm3(Predicted)

反应信息

• 作为产物：
  描述：

  1-trifluoromethyl-4-methylcyclohexan-1-ol 在 platinum(IV) oxide 吡啶 、 4-二甲氨基吡啶 、 氯化亚砜 、 氢气 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 25.0~50.0 ℃ 、100.0 kPa 条件下， 反应 6.0h， 生成 cis-1-trifluoromethyl-4-methylcyclohexane
  参考文献：
  名称：

  在超声辐射下通过全氟烷基烯烃的氢化方便地合成氟化烷烃和环烷烃

  摘要：

  在室温下，在大气压下，在室温下，通过氢化位阻和电子贫乏的全氟烷基烯烃，合成几种1,4-二取代的环己烷。如果不使用超声波，无论使用何种催化剂和压力（1至120 bar），都难以实现加氢。超声辐射与金属催化的耦合极大地提高了全氟烷基烯烃的氢化效率。

  DOI：

  10.1016/j.jfluchem.2005.07.006

文献信息

• [EN] 3H-IMIDAZO [4, 5 -C] PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS<br/>[FR] 3H-IMIDAZO[4,5-C]PYRIDINE-6-CARBOXAMIDES EN TANT QU'ANTI-INFLAMMATOIRES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010100249A1

  公开（公告）日：2010-09-10

  The present invention relates to compounds of general formula (I) in which A, L, M, Q2, Q3, Q4, R1, R5, Ra, Rb, Rc, W, X, Y, Z1, Z2, Z3 are defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof. The compounds are of potential utility in the treatment and/or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and/or prevention of pain. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.

  本发明涉及通式(I)中的化合物，其中A、L、M、Q2、Q3、Q4、R1、R5、Ra、Rb、Rc、W、X、Y、Z1、Z2、Z3在描述中有定义，及其盐，特别是其生理上可接受的盐。这些化合物可能在治疗和/或预防炎症性疾病及相关症状方面具有潜在的用途，特别是在治疗和/或预防疼痛方面。本发明还涉及将这些化合物用作药物、含有它们的药物组合物以及它们的制备。
• [EN] TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS<br/>[FR] HÉTÉROCYCLES TRICYCLIQUES UTILES EN TANT QUE LIANTS TEAD
  申请人：MERCK PATENT GMBH

  公开号：WO2021224291A1

  公开（公告）日：2021-11-11

  The present invention relates to tricyclic heterocycles. These heterocyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases, in particular cancer.

  本发明涉及三环杂环化合物。这些杂环化合物可用作TEAD结合物，和/或YAP-TEAD和TAZ-TEAD蛋白质间的相互作用或结合的抑制剂，用于预防和/或治疗包括过度增殖性疾病和疾病在内的多种医疗条件，特别是癌症。
• [EN] SUBSTITUTED ARYL PYRIMIDINONES<br/>[FR] ARYL PYRIMIDINONES SUBSTITUÉS
  申请人：NEUROGEN CORP

  公开号：WO2009100403A1

  公开（公告）日：2009-08-13

  Substituted aryl pyrimidinones are provided, of the Formula (I) wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

  提供了替代芳基嘧啶酮，其化学式为（I），其中变量如本文所述。这些化合物是配体，可用于调节体内或体外特定受体的活性，并且在治疗与人类、家养伴侣动物和家畜动物中的病理性受体激活相关的疾病方面特别有用。提供了用于治疗这些疾病的药物组合物和方法，以及用于受体定位研究的配体的使用方法。
• PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF
  申请人：Boyle Craig D.

  公开号：US20100190687A1

  公开（公告）日：2010-07-29

  The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of G protein-coupled receptor 119 (“GPR119”) in a patient.

  本发明涉及嘧啶酮衍生物，包含嘧啶酮衍生物的组合物，以及使用嘧啶酮衍生物治疗或预防肥胖、糖尿病、代谢紊乱、心血管疾病或与G蛋白偶联受体119（“GPR119”）活性相关的疾病的方法。
• HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS
  申请人：Takahashi Akira

  公开号：US20120065189A1

  公开（公告）日：2012-03-15

  The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R 1 and R 2 , each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R 3 represents a lower alkynyl group or the like; R 4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.

  本发明提供了一种新型杂环化合物。所述杂环化合物的通式（1）表示，其中，R1和R2各自独立地表示氢；苯基低烷基，其可以在苯环上和/或低烷基上具有选自低烷基等的取代基；或环状C3-C8烷基低烷基；或类似物；R3表示低炔基或类似物；R4表示苯基，其可以具有选自1,3,4-噁二唑基（例如，卤素）或选自吡啶基等杂环基的取代基；所述杂环基可以具有至少一个选自低烷氧基等的取代基或其盐。